- Conditions
- Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA
- Interventions
- Anal Pap smear and HPV DNA testing
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 310 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 3,221
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity
- Interventions
- Folic acid
- Dietary Supplement
- Lead sponsor
- University of Georgia
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Athens, Georgia
- Conditions
- Measles, Mumps, Rubella, Varicella
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 16 Months
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
- Interventions
- Multi-analyte Blood Test
- Diagnostic Test
- Lead sponsor
- Helio Genomics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Timeline
- 2019 – 2028
- U.S. locations
- 7
- States / cities
- Redondo Beach, California • Coon Rapids, Minnesota • Fridley, Minnesota + 4 more
- Conditions
- Breast Cancer
- Interventions
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review, evaluation of cancer risk factors
- Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 19 Years to 80 Years · Female only
- Enrollment
- 316 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- HIV Infections
- Interventions
- GEO-D03 DNA vaccine, MVA/HIV62B (MVA62B) vaccine, Placebo for GEO-D03 DNA, Placebo for MVA62B:
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 1 more
- Conditions
- Adenovirus
- Interventions
- Brincidofovir
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 2 Months to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Washinton, District of Columbia • Atlanta, Georgia + 17 more
- Conditions
- Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma, Small Lymphocytic Lymphoma, Transformed Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells
- Drug · Biological
- Lead sponsor
- C. Babis Andreadis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- DNA Damage, Psychological Stress
- Interventions
- Propranolol, Placebo oral capsule, Acute stress task, No stress task
- Drug · Behavioral
- Lead sponsor
- Dana Bovbjerg
- Other
- Eligibility
- 20 Years to 59 Years
- Enrollment
- 239 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Chronic Hepatitis B
- Interventions
- Entecavir
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 28 more
- Conditions
- Head and Neck Neoplasm, Carcinoma, Squamous Cell
- Interventions
- Blood and tumor samples
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Prostate Cancer
- Interventions
- pTVG-HP with rhGM-CSF
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Chronic Hepatitis B
- Interventions
- TAF, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 12 more
- Conditions
- Merkel Cell Carcinoma, Skin Cancer
- Interventions
- Nivolumab, Ipilimumab, Stereotactic Body Radiation Therapy (SBRT)
- Drug · Radiation
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Columbus, Ohio
- Conditions
- Angina Pectoris
- Interventions
- pVGI.1(VEGF2)
- Genetic
- Lead sponsor
- Corautus Genetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 27 more
- Conditions
- Breast Cancer
- Interventions
- Pegylated liposomal doxorubicin
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Albuquerque, New Mexico
- Conditions
- B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Human Papilloma Virus Infection
- Interventions
- Not listed
- Lead sponsor
- Gen-Probe, Incorporated
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11,816 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 3
- States / cities
- San Diego, California • Minneapolis, Minnesota • Burlington, North Carolina
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Interventions
- Biopsy Procedure, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Computed Tomography, Dasatinib, Echocardiography Test, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate, X-Ray Imaging
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 65 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 195
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 139 more
- Conditions
- Gynecologic Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer, Lynch Syndrome, Hereditary Breast and Ovarian Cancer Syndrome, Colon Cancer, Endometrial Cancer, Uterus Cancer
- Interventions
- Free genetic testing and counseling group, IGNITE-TX Group, IGNITE-TX and free genetic testing and counseling group
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hereditary Cancer Syndrome
- Interventions
- Modified genetic counseling, Traditional genetic counseling
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 967 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Portland, Oregon
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Interventions
- VP-102
- Combination Product
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Bowling Green, Kentucky • Owensboro, Kentucky • New York, New York + 1 more
- Conditions
- Metastatic Triple Negative Breast Cancer
- Interventions
- Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 17 more
- Conditions
- Healthy Men, Healthy Women
- Interventions
- Control, Garlic treatment
- Other
- Lead sponsor
- USDA Beltsville Human Nutrition Research Center
- Federal
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Beltsville, Maryland